Overview
Myriad Genetics, Inc., based in the United States, operates prominently within the biotechnology industry, focusing primarily on molecular diagnostics and personalized medicine. Established with the aspiration to advance patient care through genetic insights, Myriad Genetics specializes in developing and marketing predictive, personalized, and prognostic tests across various medical disciplines. Its key projects include pioneering work in hereditary cancer screening, particularly with the BRCA gene tests, and expansions into tests for depression medication response (GeneSight) and rheumatoid arthritis. The company emphasizes innovation in genetic research to facilitate early disease detection and optimized treatment, reflecting its commitment to enhancing patient health outcomes through cutting-edge genetic screening technologies.
Basic Stats
The share price of Myriad Genetics, Inc. as of September 5, 2025 is $6.60 / share. This is an increase of 3.69% from the prior week. The market cap (or net worth) of Myriad Genetics, Inc. as of September 5, 2025 is $614.93 MM.
The Factor Analysis chart (below right) shows a view of Myriad Genetics, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 614.93 MM |
| EV | 659.23 MM |
| Shares Out. | 93.10 MM |
| Earnings Date | |
| EPS (TTM) | -4.24 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.94 |
| Short Shares Avail. | 4.30 MM |
| Short Interest | 9.37 MM |
| Short Float | 10.95 % |
| Days to Cover | 8.14 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | -76.12 % |
| Volatility (1 yr) | 0.85 |
| Beta | 0.66 |
| Sharpe Ratio (1 yr) | -0.95 |
| Sortino Ratio (1 yr) | -1.48 |
| PE Ratio | -1.56 |
| Price/Book | 1.58 |
| Price/TBV | 3.70 |
| Book/Market | 0.63 |
| EBIT/EV | -0.64 |
| EBIT(3yr avg)/EV | -0.43 |
| ROA | -0.36 |
| ROE | -0.53 |
| ROIC | -0.66 |
| CROIC | -0.03 |
| OCROIC | -0.04 |
| Implied Volatility | 88.49 % |
| Put/Call OI Ratio | 0.09 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Myriad Genetics, Inc. is $7.31. The forecasts range from a low of $3.54 to a high of $18.90. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Myriad Genetics, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-01-18 | Raymond James | Market Perform | Outperform | Upgrade |
| 2022-11-02 | SVB Leerink | Market Perform | Maintains | |
| 2022-10-06 | Stephens & Co. | Equal-Weight | Initiate | |
| 2022-08-05 | SVB Leerink | Market Perform | Maintains | |
| 2022-05-05 | SVB Leerink | Market Perform | Maintains | |
| 2022-04-19 | Goldman Sachs | Sell | Maintains | |
| 2021-11-03 | SVB Leerink | Market Perform | Maintains | |
| 2021-06-15 | Raymond James | Market Perform | Initiate | |
| 2021-06-03 | Goldman Sachs | Sell | Initiate | |
| 2021-02-24 | SVB Leerink | Market Perform | Maintains | |
| 2020-05-06 | JP Morgan | Underweight | Maintains | |
| 2020-04-02 | B of A Securities | Underperform | Reiterate | |
| 2020-03-26 | Barclays | Underweight | Maintains | |
| 2019-09-26 | Bank of America | Neutral | Underperform | Downgrade |
| 2019-08-14 | Piper Jaffray | Overweight | Equal-Weight | Downgrade |
| 2019-08-14 | Deutsche Bank | Hold | Maintains | |
| 2019-08-05 | Deutsche Bank | Hold | Maintains | |
| 2019-08-02 | Bank of America | Underperform | Neutral | Upgrade |
| 2019-07-29 | Needham | Strong Buy | Hold | Downgrade |
| 2019-07-09 | Cowen & Co. | Outperform | Market Perform | Downgrade |
| 2019-01-04 | Cowen & Co. | Market Perform | Outperform | Upgrade |
| 2019-01-03 | Needham | Strong Buy | Initiate | |
| 2019-01-03 | Barclays | Underweight | Underweight | Maintains |
| 2018-11-30 | Goldman Sachs | Sell | Neutral | Upgrade |
| 2018-11-05 | Deutsche Bank | Hold | Hold | Maintains |
| 2018-10-10 | PiperJaffray | Neutral | Overweight | Upgrade |
| 2018-10-10 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2018-09-11 | Barclays | Underweight | Underweight | Maintains |
| 2018-09-05 | Barclays | Equal-Weight | Underweight | Downgrade |
| 2018-08-28 | Leerink Swann | Market Perform | Market Perform | Maintains |
| 2018-08-22 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2018-08-22 | Barclays | Equal-Weight | Equal-Weight | Maintains |
| 2018-08-22 | Bank of America | Underperform | Underperform | Maintains |
| 2018-07-16 | Bank of America | Underperform | Underperform | Maintains |
| 2018-07-11 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2018-05-09 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2018-03-21 | Morgan Stanley | Underweight | Equal-Weight | Upgrade |
| 2018-02-07 | Morgan Stanley | Underweight | Underweight | Maintains |
| 2018-02-07 | Leerink Swann | Market Perform | Market Perform | Maintains |
| 2018-01-29 | Goldman Sachs | Sell | Initiate | |
| 2018-01-05 | BTIG Research | Buy | Initiate | |
| 2017-11-08 | Morgan Stanley | Underweight | Maintains | |
| 2017-11-08 | Deutsche Bank | Hold | Maintains | |
| 2017-10-06 | Morgan Stanley | Underweight | Maintains | |
| 2017-10-02 | Leerink Swann | Market Perform | Initiate | |
| 2017-08-18 | Deutsche Bank | Sell | Hold | Upgrade |
| 2017-08-09 | Barclays | Equal-Weight | Maintains | |
| 2017-02-08 | Ladenburg Thalmann | Sell | Neutral | Upgrade |
| 2017-01-18 | Deutsche Bank | Sell | Initiate | |
| 2016-11-02 | Stephens & Co. | Overweight | Equal-Weight | Downgrade |
| 2016-10-10 | Ladenburg Thalmann | Neutral | Sell | Downgrade |
| 2016-10-10 | Barclays | Equal-weight | Maintains | |
| 2016-08-11 | Jefferies | Hold | Maintains | |
| 2016-08-10 | Wells Fargo | Outperform | Market Perform | Downgrade |
| 2016-08-10 | UBS | Sell | Maintains | |
| 2016-08-10 | PiperJaffray | Overweight | Neutral | Downgrade |
| 2016-08-10 | Morgan Stanley | Underweight | Maintains | |
| 2016-08-10 | Gabelli & Co. | Buy | Hold | Downgrade |
| 2016-08-10 | Barclays | Overweight | Equal-Weight | Downgrade |
| 2016-07-29 | Bank of America | Neutral | Underperform | Downgrade |
| 2016-05-04 | Leerink Swann | Market Perform | Maintains | |
| 2016-05-04 | Avondale Partners | Market Outperform | Maintains | |
| 2016-01-06 | Deutsche Bank | Buy | Initiate | |
| 2016-01-06 | Avondale Partners | Market Outperform | Initiate | |
| 2015-12-08 | Goldman Sachs | Sell | Neutral | Upgrade |
| 2015-09-16 | Stephens & Co. | Overweight | Maintains | |
| 2015-09-15 | PiperJaffray | Overweight | Maintains | |
| 2015-09-15 | Jefferies | Hold | Maintains | |
| 2015-08-25 | Wells Fargo | Market Perform | Outperform | Upgrade |
| 2015-08-12 | JMP Securities | Market Outperform | Maintains | |
| 2015-05-06 | JMP Securities | Market Outperform | Maintains | |
| 2015-03-26 | Goldman Sachs | Neutral | Sell | Downgrade |
| 2015-03-10 | UBS | Sell | Initiate | |
| 2015-02-04 | Mizuho | Buy | Neutral | Downgrade |
| 2015-02-04 | JMP Securities | Market Perform | Market Outperform | Upgrade |
| 2015-02-04 | Credit Suisse | Neutral | Underperform | Downgrade |
| 2014-11-10 | Morgan Stanley | Underperform | Initiate | |
| 2014-08-15 | Credit Suisse | Neutral | Maintains | |
| 2014-06-05 | Macquarie | Neutral | Maintains | |
| 2014-05-13 | Credit Suisse | Neutral | Maintains | |
| 2014-04-14 | Bank of America | Neutral | Maintains | |
| 2014-04-04 | Mizuho | Neutral | Buy | Upgrade |
| 2014-02-07 | Credit Suisse | Underperform | Neutral | Upgrade |
| 2014-02-05 | Ladenburg Thalmann | Buy | Neutral | Downgrade |
| 2014-02-05 | JMP Securities | Market Underperform | Market Perform | Upgrade |
| 2013-12-31 | Bank of America | Neutral | Maintains | |
| 2013-12-30 | Mizuho | Buy | Neutral | Downgrade |
| 2013-12-03 | JMP Securities | Market Outperform | Market Perform | Downgrade |
| 2013-11-06 | Jefferies | Hold | Maintains | |
| 2013-10-22 | Jefferies | Hold | Maintains | |
| 2013-10-21 | Credit Suisse | Neutral | Underperform | Downgrade |
| 2013-10-11 | SunTrust Robinson Humphrey | Reduce | Initiate | |
| 2013-10-10 | SunTrust Robinson Humphrey | Reduce | Initiate | |
| 2013-10-01 | Ladenburg Thalmann | Neutral | Buy | Upgrade |
| 2013-06-14 | RBC Capital | Outperform | Sector Perform | Downgrade |
| 2013-06-14 | JMP Securities | Market Perform | Market Outperform | Upgrade |
| 2013-06-14 | Bank of America | Buy | Neutral | Downgrade |
| 2013-06-13 | Leerink Swann | Outperform | Market Perform | Downgrade |
| 2013-06-06 | Cantor Fitzgerald | Buy | Initiate | |
| 2013-05-31 | Jefferies | Hold | Initiate | |
| 2013-05-08 | Mizuho | Neutral | Buy | Upgrade |
| 2013-03-04 | Oppenheimer | Perform | Maintains | |
| 2013-03-04 | Jefferies | Buy | Maintains | |
| 2013-02-05 | Ladenburg Thalmann | Buy | Neutral | Downgrade |
| 2013-01-03 | JP Morgan | Neutral | Underweight | Downgrade |
| 2012-12-03 | Mizuho | Buy | Neutral | Downgrade |
| 2012-12-03 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2012-11-06 | Jefferies | Buy | Maintains | |
| 2012-10-24 | Bank of America | Neutral | Buy | Upgrade |
| 2012-10-01 | PiperJaffray | Neutral | Overweight | Upgrade |
| 2012-09-25 | Credit Suisse | Neutral | Initiate | |
| 2012-07-02 | Goldman Sachs | Neutral | Buy | Upgrade |
| 2012-05-11 | Bank oferica | Neutral | Initiate | |
| 2012-05-02 | Jefferies | Buy | Maintains | |
| 2023-03-06 | Stephens & Co. | Equal-Weight | Maintains | |
| 2023-03-03 | Raymond James | Outperform | Maintains | |
| 2023-05-04 | Stephens & Co. | Equal-Weight | Reiterate | |
| 2023-05-04 | Goldman Sachs | Sell | Maintains | |
| 2023-05-23 | Goldman Sachs | Sell | Buy | Upgrade |
| 2023-05-24 | Goldman Sachs | Buy | Buy | Maintains |
| 2024-01-30 | Goldman Sachs | Buy | Buy | Maintains |
| 2023-07-24 | Goldman Sachs | Buy | Buy | Maintains |
| 2023-08-07 | JP Morgan | Underweight | Underweight | Maintains |
| 2023-11-07 | JP Morgan | Underweight | Underweight | Maintains |
| 2023-07-21 | Goldman Sachs | Buy | Buy | Maintains |
| 2023-12-13 | Wolfe Research | Outperform | Initiate | |
| 2023-12-19 | Wells Fargo | Equal-Weight | Initiate | |
| 2023-12-14 | Guggenheim | Buy | Initiate | |
| 2023-12-21 | Piper Sandler | Neutral | Initiate | |
| 2024-05-08 | Leerink Partners | Market Perform | Outperform | Upgrade |
| 2024-01-29 | Goldman Sachs | Buy | Buy | Maintains |
| 2024-05-13 | Piper Sandler | Neutral | Neutral | Maintains |
| 2024-06-27 | Scotiabank | Sector Outperform | Initiate | |
| 2025-01-30 | Piper Sandler | Neutral | Neutral | Maintains |
| 2024-08-27 | Wells Fargo | Overweight | Initiate | |
| 2025-01-28 | Goldman Sachs | Buy | Buy | Maintains |
| 2024-08-07 | TD Cowen | Hold | Hold | Maintains |
| 2024-08-07 | JP Morgan | Underweight | Underweight | Maintains |
| 2024-12-13 | B of A Securities | Underperform | Underperform | Maintains |
| 2025-05-07 | Raymond James | Outperform | Outperform | Reiterate |
| 2025-05-07 | UBS | Neutral | Neutral | Maintains |
| 2025-05-07 | Goldman Sachs | Buy | Buy | Maintains |
| 2025-02-12 | Craig-Hallum | Buy | Initiate | |
| 2024-12-09 | Leerink Partners | Outperform | Market Perform | Downgrade |
| 2025-01-16 | Stephens & Co. | Equal-Weight | Equal-Weight | Reiterate |
| 2024-11-18 | Morgan Stanley | Equal-Weight | Equal-Weight | Maintains |
| 2024-11-11 | Piper Sandler | Neutral | Neutral | Maintains |
| 2025-02-25 | UBS | Neutral | Neutral | Maintains |
| 2025-02-25 | Raymond James | Outperform | Outperform | Reiterate |
| 2024-12-10 | UBS | Neutral | Initiate | |
| 2024-08-13 | Scotiabank | Sector Outperform | Sector Outperform | Maintains |
| 2024-08-13 | Piper Sandler | Neutral | Neutral | Maintains |
| 2024-09-19 | Morgan Stanley | Equal-Weight | Initiate | |
| 2025-03-03 | B of A Securities | Underperform | Underperform | Maintains |
| 2025-03-12 | Piper Sandler | Neutral | Overweight | Upgrade |
| 2025-04-01 | Scotiabank | Sector Outperform | Sector Outperform | Maintains |
| 2025-05-15 | Piper Sandler | Overweight | Overweight | Maintains |
| 2025-03-04 | Piper Sandler | Neutral | Neutral | Maintains |
| 2025-04-09 | Guggenheim | Buy | Neutral | Downgrade |
| 2025-04-17 | Goldman Sachs | Buy | Buy | Maintains |
| 2025-05-08 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
| 2025-05-21 | Scotiabank | Sector Outperform | Sector Perform | Downgrade |
